Research programme: small molecule therapeutics - Sanofi
Latest Information Update: 31 Mar 2022
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Small molecules
- Mechanism of Action Proto oncogene protein c pim 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 May 2006 No development reported - Preclinical for Cancer in USA (unspecified route)
- 12 Mar 2004 This programme is still in active development